150 related articles for article (PubMed ID: 37293147)
1. Exosomal transfer of miR-548aq-3p confers cisplatin resistance
Shi Y; Zou Y; Guo Y; Liu Y; Wang Q
Am J Cancer Res; 2023; 13(5):1999-2012. PubMed ID: 37293147
[TBL] [Abstract][Full Text] [Related]
2. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
[TBL] [Abstract][Full Text] [Related]
3. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract][Full Text] [Related]
4. miR-548aq-3p is a novel target of Far infrared radiation which predicts coronary artery disease endothelial colony forming cell responsiveness.
Tsai WC; Chiang WH; Wu CH; Li YC; Campbell M; Huang PH; Lin MW; Lin CH; Cheng SM; Chang PC; Cheng CC
Sci Rep; 2020 Apr; 10(1):6805. PubMed ID: 32322002
[TBL] [Abstract][Full Text] [Related]
5. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
6. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
7. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
8. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
[TBL] [Abstract][Full Text] [Related]
9. [Effect of circBIRC6 targeting miR-367-3p on cisplatin resistance of ovarian cancer cells].
Zhang J; Bai HJ
Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1062-1068. PubMed ID: 34695896
[No Abstract] [Full Text] [Related]
10. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
11. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
12. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
[TBL] [Abstract][Full Text] [Related]
13. MiR-513a-3p inhibits EMT mediated by HOXB7 and promotes sensitivity to cisplatin in ovarian cancer cells.
Chen Y; Zhao XH; Zhang DD; Zhao Y
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10391-10402. PubMed ID: 33155195
[TBL] [Abstract][Full Text] [Related]
14. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
15. MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.
Tian J; Xu YY; Li L; Hao Q
Am J Transl Res; 2017; 9(3):1127-1138. PubMed ID: 28386339
[TBL] [Abstract][Full Text] [Related]
16. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
Xu ZH; Yao TZ; Liu W
Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
[TBL] [Abstract][Full Text] [Related]
17. miR-152-3p Sensitizes Glioblastoma Cells Towards Cisplatin Via Regulation Of SOS1.
Wang M; Wu Q; Fang M; Huang W; Zhu H
Onco Targets Ther; 2019; 12():9513-9525. PubMed ID: 31807027
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblast-derived exosomal microRNA-24-3p enhances colon cancer cell resistance to MTX by down-regulating CDX2/HEPH axis.
Zhang HW; Shi Y; Liu JB; Wang HM; Wang PY; Wu ZJ; Li L; Gu LP; Cao PS; Wang GR; Ma YS; Fu D
J Cell Mol Med; 2021 Apr; 25(8):3699-3713. PubMed ID: 33621425
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.
Wang B; Zhang Y; Ye M; Wu J; Ma L; Chen H
Curr Drug Metab; 2019; 20(10):804-814. PubMed ID: 31424364
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells.
Miyamoto M; Sawada K; Nakamura K; Yoshimura A; Ishida K; Kobayashi M; Shimizu A; Yamamoto M; Kodama M; Hashimoto K; Kimura T
Sci Rep; 2020 Oct; 10(1):16755. PubMed ID: 33028939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
